Cargando…
Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
BACKGROUND: Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia. SUMMARY: Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900466/ https://www.ncbi.nlm.nih.gov/pubmed/36756084 http://dx.doi.org/10.1159/000527835 |